Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer's disease: a systematic review and meta-analysis. (PubMed, Front Pharmacol) - Oct 14, 2026 - "Nevertheless, lecanemab was associated with an increased risk of TEAEs and headache. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251146867."
Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • Hematological Disorders • Infectious Disease • Nephrology • Pain
|
|
Aiqun Liu; Han-Biao Wu; Jia-Xin Zhang; Jisheng Chen; Long-Zhuan Huang; Sha Lai; Shang-Ying Li; Yu-Bing Ye
|